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REVIEW
Use of functional imaging across clinical phases in
CNS drug development
D Borsook1,2,3,4,5,6, L Becerra1,2,3,4,5,6 and M Fava2,4,6
The use of novel brain biomarkers using nuclear magnetic resonance imaging holds potential of making central nervous system
(CNS) drug development more efficient. By evaluating changes in brain function in the disease state or drug effects on brain
function, the technology opens up the possibility of obtaining objective data on drug effects in the living awake brain. By
providing objective data, imaging may improve the probability of success of identifying useful drugs to treat CNS diseases
across all clinical phases (I–IV) of drug development. The evolution of functional imaging and the promise it holds to contribute
to drug development will require the development of standards (including good imaging practice), but, if well integrated into drug
development, functional imaging can define markers of CNS penetration, drug dosing and target engagement (even for drugs
that are not amenable to positron emission tomography imaging) in phase I; differentiate objective measures of efficacy and side
effects and responders vs non-responders in phase II, evaluate differences between placebo and drug in phase III trials and
provide insights into disease modification in phase IV trials.
Translational Psychiatry (2013) 3, e282; doi:10.1038/tp.2013.43; published online 16 July 2013
Introduction
As noted in a historical review on drug development, the
process has evolved from a chemistry-based process to
integrating pharmacology and clinical sciences to the con-
tributions of molecular biology and genomics.1 However, the
complexity of the brain makes central nervous system (CNS)
drug discovery a real challenge. In the past, even with
significant investment in basic neuroscience, the majority of
clinical trials have failed to translate into measurable clinical
benefit. Notwithstanding the enormous developments in
neuroscience, systems neurobiology, nuclear magnetic reso-
nance (NMR) imaging in health and disease are clearly
making their mark in questioning new approaches to drug
development. With the advent of new techniques in functional
neuroimaging, the ability to evaluate disease state and drug
effects on neural systems in clinical populations has opened
the door to adopting new approaches to CNS drug develop-
ment particularly in clinical trials.
Over the past few decades, CNS drug development has
been hampered by countless negative and failed double blind,
placebo-controlled trials—trials that have failed to confirm the
expected superiority of both novel and standard compounds
over a placebo condition. Negative findings with promising
new agents have often led to premature shelving of such
compounds and many large pharmaceutical companies have
gradually abandoned their focus on CNS drug development
because of the perception that trials in this area are ‘risky,’
given the greater than 50% of failure in adequately powered
trials.2 These negative trials have also caused delays in
bringing new treatments to the market, increased costs of
drug development, and, in some cases, Food and Drug
Administration (FDA) decisions not to approve new treat-
ments (‘for the preponderance of negative data’). An analysis
in JAMA3 of 75 double-blind antidepressant trials, which had
been conducted among patients with major depressive
disorder and had been published between January 1981
and December 2000, showed that the response to placebo
was often substantial and progressively increasing, with a
significant positive relationship between year of publication
and response rate. The gradual increase in placebo response
rates across psychiatric disorders is a worrisome phenom-
enon, which has had a dramatic impact on the clinical
development of new therapeutic agents. The two biggest
factors that contribute to the extremely high rate of failures of
CNS clinical trials are misclassification of study subjects (for
example, the patients do not have the disease under
investigation or have much milder forms than those required)
and the excessive placebo response. These issues are highly
salient since, while there remains a high demand for new and
effective treatments for CNS disorders (for example, depres-
sion, pain, Alzheimer’s disease, seizure disorders and so on),
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the risk is such that many of the large pharmaceutical
companies have withdrawn from this drug development
arena. The lack of new drugs speaks to a problem that exists
in the field—that old practices do not work and that new and
innovative approaches are urgently needed.4 Indeed some
have termed these difficulties as contributing to ‘the death of
CNS drug development’.5 Large pharmaceutical company
pullout of CNS indications is leaving a large gap in the CNS
drug development line and the clinical unmet need will require
other adaptive strategies such as smaller biotech or the
advent of better approaches to discover and develop new
agents for treating disorders of the brain andmind. An imaging
approach across drug development (including proof of
concept paradigms)6 will help drug discovery as will fully
integrate the early development side (mainly bottom-up) with
clinical trials (mainly top-down).
Subjective ratings in CNS disorders
Subjective ratings are highly variable. Yet this is by and large
what has become a major determinant of outcome in CNS
trials, which often rely on clinician-rated measurements that
are subjects to various biases. It is a complex issue
confounded by placebo effect, the lack of effect size, the
undulating or changing nature of the disease. Inter-individual
differences relate to biology, disease state, psychological
phenomena and the consistency of the instrument/s used to
measure outcomes. Even for the same stimulus, different
scales have differences in reliability.7,8 In these cases, we are
not even considering an individual’s ability (education,
cognitive ability—innate or due to disease such as neurode-
generative conditions; depression and so on) that may bias
the outcome. Inadequate response may also be a concern
that relate to dosing, duration of treatment and other factors.
The harbinger of clinical trial failure has included high placebo
responses. Many contributing factors to high placebo
response rates observed in CNS clinical trials have been
identified, such as diagnostic misclassification, issues con-
cerning inclusion/exclusion criteria, outcome measures’ lack
of sensitivity to change, measurement errors, misclassifica-
tion of treatment outcome, waxing and waning of the natural
course of illness, regression toward the mean phenomenon,
study designs fostering high patient and clinician expecta-
tions, nonspecific therapeutic effects and high attrition rates.9
Three of these elements are thought to represent the most
critical factors in yielding high placebo response rates:
diagnostic misclassification, misclassification of treatment
outcome and study designs fostering high patient and clinician
expectations. Clinical trial design is becoming more sophis-
ticated including enrichment trials (see Fava et al. 10and Chen
et al.11). New approaches include the ‘Sequential Parallel
Comparison Design’,9 suitable for double-blind, placebo-
controlled trials in CNS disorders. This design is aimed at
reducing both the overall placebo response rate and the
sample size required for such trials. The basic idea is to have
two phases of treatment. The first phase involves an
unbalanced randomization between placebo and active
treatment with more patients randomized to placebo. In the
second phase, non-responders treated with placebo are
randomized to either active treatment or placebo. As patients
on the second phase have already ‘failed placebo’, their
placebo response is expected to be reduced. The analysis
pools the data from both phases in order to maximize power
and reduce the required sample size (see http://clinicaltrials.
gov/ct2/show/record/NCT01318434). Thus far, three Seq-
uential Parallel Comparison Design trials of CNS compounds
have been completed and published, yielding weighted
averages of placebo response rates markedly lower than
those observed in standard designs.12,13
Given the state of the art, there would appear to be some
new impetus to utilizing new14 technologies to help improve
trial information and outcomes. One such approach that is
being applied with greater seriousness is that of functional
imaging of brain systems. Here we review the nature of how
imaging may contribute across Clinical Trials both as a
contributor to new information and also providing insights into
integration of information across phases of clinical trials. We
have termed this as imaging in Drug Development.
Current issues in CNS drug development and potential
opportunities through imaging
Capturing data of functional effects of drug action in the living
human brain of healthy volunteers or patients bring with it new
opportunities to understand drug effects on CNS circuits in a
manner that should transform CNS drug development. We
discuss some of these processes across each phase (I–IV),
noting some of the issues that are faced and provide support
for how the use of imaging may either overcome or at least
mitigate some of these hurdles. The major contributions relate
to objectifying information in a rapid and specific manner.
Integration of imaging processes across the drug development
process can determine short-term effects (for example, CNS
penetration and dosing), intermediate effects (for example,
targets for symptom relief, possible side effects) and long-term
drug effects (for example, diseasemodification). As suggested
in the discussion below, although imaging may find useful
applications across each phase, there are dominant roles
suggested for phase I (evaluative imaging); phase II (effective
imaging—disease targeting); phase III (definitional imaging—
diminishing the variance of trials, defining responders vs non-
responders; disease modification).
Imaging concepts
Details of imaging methods can be found elsewhere but a
few concepts that relate to what can bemeasured are noted in
Box 1.
Phase I
Phase I trials ‘test an experimental drug or treatment in a small
group of people20–79 for the first time to evaluate its safety,
determine a safe dosage range and identify side effects’
(www.clinicaltrials.gov). Few drugs (approximately 1 in 10)
that are evaluated in preclinical phases make it to phase I
testing in humans. First-in-human (FIH) doses are clearly
fraught with how best to protect subjects.35 Once a drug (new
chemical entity) is approved for FIH by a federal agency (for
example, the FDA or the European Medicines Agency
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(EMA)), initial phase I studies are conducted, usually in
healthy volunteers, to determine safety and dosing (viz.,
toxicity, pharmacokinetics and metabolism). More recently,
phase I studies are beginning to include subjects with the CNS
disease that is ultimately targeted by the compound under
development. When this happens, it becomes critical to ensure
that subjects do suffer from the CNS disease under investiga-
tion, it is also critical to provide greater information on the CNS
effects of the compound studied and subjective ratings are
often grossly inadequate in providing information on CNS
penetration and targeting. It is a this time and going forward,
significant increases in costs are associated with drug
development and processes that can provide objective data
for go–nogo decisions are critical for efficient development
programs. For those drugs with CNS indications, the additional
focus on CNS-related processes is required (for example, CNS
penetration). Clearly maximizing information at this and later
stages of clinical trial, drug development is clearly desirable and
warranted. As noted by Dresser,36 ethical issues are being
spotlighted as translational science approaches are inevitably
leading to increases in FIH trials.
CNS penetration and targeting. The blood–brain barrier
can limit penetration of drugs into the CNS37 and effective
measures of drug penetration into the CNS for CNS-acting
drugs are clearly critical—both from the point of view of how
much crosses the blood–brain barrier and how best to
choose an effective dose to achieve effective/therapeutic
levels. CNS-acting drugs can be measured for their penetra-
tion using cerebrospinal fluid levels or specific brain markers
(for example, positron emission tomographic-based receptor
ligands). In addition, positron emission tomography (PET)
tracers can define drug targets (target engagement) within
the brain. However, there are issues that the ligand-based
approach does not provide: (1) functional responses to the
drug effective engagement; (2) functional dose responses
related to the drug of interest; and (3) for many drugs, the
development of a specific ligand for PET is not possible.29,38
Imaging opportunity. Pharmacological magnetic resonance
imaging (phMRI) allows for the direct (effects of drug on brain
systems) and indirect (effects of drug on responses)
evaluation of drug action in humans in early phase studies.29
Examples of phMRI use for evaluation of drugs in humans
are numerous (examples of direct measures include bupre-
norphine;22 fosaprepitant;39 mirtazapine).40 It should be
pointed out that simple phMRI activation, while it may confer
some information of drug-brain (receptor/s) activation, the
efficacy of the drug might depend more on functional
connectivity of how the drug affects certain brain circuits.22,23
Thus, in a few patients important data on CNS penetration
can be assessed. Taken into context with known pharmaco-
kinetic and pharmacodynamic profiles, the time for changes
in brain systems can also validate expected timelines for
effective CNS ‘functional dosing’. Here we define functional
dosing as the minimal dose (or early dose effects) that
produces significant activation or alteration in brain circuits.
Thus, in a few subjects valuable early data can be obtained
for most CNS-acting drugs in early or FIH trials. This is an
initial but major opportunity for the utility of imaging to
Box 1: Imaging concepts in measures of drug effects
Bold: The blood oxygenation level dependence is the main
approach tomeasure brain activity through fMRI. Based on
an interplay of local brain blood flow and volume
associated with neuronal activity assesses indirectly the
level of neuronal responses to stimuli, such as sensory or
pharmacological inputs. Effectiveness of pharmacological
treatments in patients can be evaluated across CNS
disease-related function (examples: see refs.15–19) or
differentiation of drugs20,21 or drug dosing 22,23).
Resting state networks (RSNs): One of the exciting devel-
opment is the use of BOLD tomeasure RSNs; these are low-
level spontaneous fluctuations in the BOLD signal during rest
that reflect the neuronal baseline activity of the brain.24 As
such, they can differentiate disease state or drug effects.25–27
Connectivity measurements: Repeated BOLD measure-
ments of brain activity have been utilized to determine brain
networks associated with basal brain function as well as
alteration in the disease state or drug effects.22,28 Recently,
series of basal networks in the healthy state have been
identified and their modification in different diseases estab-
lished. Inspection of the functional role of each of these
networks permits correlate observed behavioral outcomes in
diseases and the concomitant correction of these changes
when disease is resolved or ameliorated.
Pharmacological fMRI (phMRI): phMRI is variant of fMRI and
refers to a particular approach of fMRI in which the specific
brain response to a CNS-acting drug is measured.29
Arterial spin labeling (ASL): Arterial spin labeling is a
technique that allows the measure of perfusion without the
use of external agents (such as contrast agents).30 More
quantitative than BOLD but with less spatial and temporal
resolution permits to capture snapshots of basal perfusion
and if necessary brain activity. Quantitative pharmacological
effects on brain activation can be evaluated using this
approach.
Morphometric measurements: Voxel base measures (VBM)
and surface base methods allow the examination of changes
in brain structures in volume and thickness. Such measures
have shown that, in the disease state, dilation and shrinkage
occur and that treatment can resolve these changes.Disease
state31 and long-term effects of drugs on brain morphometry
may be evaluated using this approach.32
Diffusion tensor imaging (DTI): DTI is an MRI technique that
measures the apparent diffusion coefficient of water mole-
cules in tissue. Improvements in the ability to capture DTI
data and analysis tools have resulted in new measurements
of white matter integrity as well as determine potential tracks
among different brain regions. Drugs (for example, ketamine
or opioids) may produce changes in whitematter tracts33 that
may reflect either direct actions or effects on neuronal bodies.
Magnetic resonance spectroscopy (MRS): MRS provides
measures of brain neurochemistry (for example, glutamate,
gamma-amino-butyric acid and so on). Chemical measures
can provide insights into drug modulation of excitatory and
inhibitory neurotransmitters systems and the potential to
predict responders and non-responders (see Harris et al.34).
fMRI in clinical trials
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contribute to the clinical evaluation of CNS-acting drugs. This
approach can be used early in clinical trials once an Investi-
gational New Drug is obtained (without special preparation
for PET ligands if these are possible); and where multiple
receptor targets may be at play, such receptor-specific ligands
are cannot be produced. Figure 1 shows details of the
potential of the use of phMRI in defining CNS dosing and
drug ‘target/s’. To date a number of phase I imaging studies
have employed true phMRI measures as reported in the
literature (for example, see Upadhyay et al.22,23,41). Imaging
could help in determining potential side effects as well as
dosing to obtain desired effect. Specifically, in the use of
combined PET—magnetic resonance imaging (MRI) sys-
tems, it will be possible to determine whether 50% receptor
occupancy (with PET) produces the desired brain response
(with functional MRI (fMRI)). Examples of fMRI in phase I
are noted in the public domain (http://clinicaltrials.gov, see
Table 1; see section ‘Where we are now?’ below). These
include measures of acute effects of tetrahydrocannabinol on
functional brain systems that included measures on reward
and memory. In these studies, end points include PK/PD
correlations of drug measures with brain function. The study
of RO4917523 by Hoffman-La Roche is perhaps more
indicative of the approach that is beginning to be used with
phase I trials by the pharmaceutical industry. The compound
is a negative modulator (antagonist) of the metabotopic
glutamate receptor subtype 5 (mGluR5; GRM5). Here a new
drug is compared with two other drugs and placebo in a
randomized crossover trial as a safety efficacy trial in 25
healthy volunteers. The primary outcome is listed ‘To
evaluate the ability of fMRI to detect and characterize the
effect of the three drugs on brain activity at rest and during
emotional stimuli’; the secondary outcomes are noted as: (i)
‘To evaluate the ability of other behavioral paradigms/scales
to detect drug effects’; (ii) ‘To correlate the fMRI measures
with the clinical/behavioral measures’; and (iii) ‘To investigate
the safety of single doses of RO4917523 in healthy
volunteers’. This study also provides an example of compar-
ing a novel agent with currently marketed drugs.
Healthy vs patients. Why use healthy subjects in clinical
trials? There are numerous issues relating to differences in
healthy vs patients including altered brain neurobiology,
differences in brain penetration across the blood–brain
barrier, many patients having had other medications or on
medications, and side-effect profile risks. Although there are
some significant benefits to evaluating CNS drug effects in
patients using imaging (noted below), most FIH trials are in
healthy volunteers. These are usually small, dose-escalation
trials to determine appropriate dose (based on safety and
side effects) for use in future trials.42 In general, healthy
subjects are used if there is little chance of patients obtaining
benefit; and patients may be used when there is a good
chance of benefit (for example, in some oncology trials).
Imaging opportunity. Imaging new drug candidate effects in
healthy humans can provide data on networks affected by
the drug (including those that are targeted for good effect and
those systems that may be involved in side effects such as
drowsiness, nausea and vomiting, addiction potential). Such
data would provide a sound baseline for differences or
similarities of the effects of the drug in a patient population
(that could easily be integrated in phase II studies). For those
who argue that phase I trials be conducted in patients who
are targeted for the indication, the same principles apply—
through the use of imaging, early definition of targets
involved. In addition, neuroimaging could be used to
independently validate the diagnosis of the CNS disorder in
those instances where there is adequate sensitivity and
specificity of the imaging tests.43–48 Figure 2 shows details of
imaging data sets from healthy and patient populations that
may provide useful information on the drug effect on normal
and abnormal circuits. The issue is salient as much of the
individual’s brain may continue to have ‘normal function’ and
thus a drug may act on these normal systems to contribute to
its efficacy. The potential for imaging in early clinical trials is
that it would seem to provide highly valuable additional data
that currently cannot be easily assayed in other ways. Such
data may provide information that may confirm the diagnosis
of the CNS disorder, may indicate which networks are
affected by the drug and may modify the future trail design
before larger more expensive trials are implemented. In
addition, early comparisons of drug effects in healthy and
patients would seem to provide optimal data on drug dosing.
For example, we and others have shown that fMRI can
contribute to understanding optimal drug dosing for CNS
effects and that the efficacy may depend on the
brain functional connectivity not simply phMRI regional
activation.22,23 One of the important missing pieces of data
Plasma PK CNS PK
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(Regions or Networks)fM
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CNS Penetration
Figure 1 Specific outcomes for magnetic resonance imaging (MRI) imaging in
phase I trials. Top: Measures of CNS penetration and brain activation. Bottom:
Indirect measures of central nervous system (CNS) dosing. The latter can be
evaluated in two ways—either through such modeling of effective increasing doses
based on concentrations evolving to Cmax. Further functional MRI (fMRI) studies
using different doses can further define effective dosing as defined by activation.
Such dosing has been shown to differentiate drug activity.23 PK, pharmacokinetics.
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Table 1 Examples of CNS acting drug trials using imaging (data collected from clinicaltrials.gov)
Drug (comparators) Indication Phase Imaging modality ClinicalTrials.gov identifier
1. Adalimumab Rheumatoid arthritis NI fMRI NCT01197144
2. Alprazolam General anxiety disorder IV fMRI NCT00662259
3. Amisulpride (Olanzapine) (Haloperidol) Schizophrenia IV fMRI/DTI NCT00419653
4. AQW051 Schizophrenia I fMRI NCT00825539
5. Aripiprazole (D-Cycloserine) Autistic disorder III fMRI NCT00198107
Aripiprazole Autistic disorder IV fMRI NCT01028820
Aripiprazole (Haloperidol) Schizophrenia I phMRI NCT01161277
6. Atomoxetine Methamphetamine abuse I fMRI NCT01019707
Atomexitine (Methylphenidate) ADHD IV fMRI NCT01678209
Atomoxetine ADHD IV fMRI NCT00716274
7. AZD6765 (Ketamine) Major depression I fMRI NCT01046630
8. Botulinum toxin A Cerebral palsy I/II fMRI NCT00503620
9. Buproprion (Escitalopram) Depression IV fMRI/MRS NCT01541475
Buproprion Healthy I fMRI NCT00205946
10. CGRP Migraine NI fMRI NCT00363532
11. Citrolam Depression NI fMRI/MRS NCT01568684
Citalopram Autism spectrum disorders I fMRI NCT00609531
Citalopramþmood Stab Bipolar depression II/III fMRI/PET NCT00562861
12. Cytokine** Model of depression 0 fMRI NCT00949845
13. Delta9-tetra-hydrocannabinol Addiction I fMRI NCT00628706
14. Desipramine Irritable bowel syndrome NI fMRI NCT00880594
15. Desvenlafaxine Depression III fMRI NCT00888862
16. Diacetylmorphine Stress/healthy I/II fMRI NCT01174927
17. Diazepam (Lorazepam) Healthy NI fMRI NCT00696033
18. Donazepil Alzheimer’s disease IV fMRI NCT00477659
Donazepil Alzheimer’s disease I/II fMRI NCT00408525
Donazepil Fragile-X I fMRI NCT00220584
19. Duloxetine Dysthymic order IV fMRI NCT00360724
Duloxetine Depression IV fMRI NCT01051466
Duloxetine Depression IV fMRI NCT00532480
Duloxetine Depression IV fMRI NCT00889369
Duloxetine Interoceptive awareness IV fMRI NCT00337012
20. Eszopiclone Sleep/pain IV fMRI NCT00414037
Eszopiclone Depression NI fMRI NCT00926653
21. Exendin-4 Alzheimer’s disease II fMRI/Mroph NCT01255163
22. Fluoxetine Depression IV fMRI NCT00188942
Fluoxetine Depression (children) NI fMRI NCT00018057
Fluoxetineþ olanzepine (olanzepine) Depression IV fMRI NCT00188942
Fluoxetine (children) Depression NI fMRI NCT00018057
Fluoxetine (children) Depression NI fMRI NCT01740726
23. Glatiramer acetate (IFN-b-1a) Multiple sclerosis IV fMRI NCT00398528
24. GSK561679 (Lorazepam) Depression I fMRI NCT00513565
25. GW679769 (Alprazolam) Social anxiety disorder I fMRI NCT00332046
26. GSK561679 (GW876008) (Alprazolam) Social anxiety disorder I fMRI NCT00555139
27. GSK598809 Food addiction I fMRI NCT01039454
28. Guanfacine Hydrochloride ADHD IV fMRI NCT01709695
29. GW876008 Irritable bowel syndrome I fMRI NCT00376896
30. Ketamine Attentiveness I fMRI NCT01165294
Ketamine Depression II fMRI NCT01135758
31. Lamotrigine Neuropathic pain NI fMRI NCT00243152
32. Leptin (Pramlintide) Obesity NI fMRI NCT00691158
33. Leviracetam Alzheimer’s II fMRI NCT01044758
Leviracetam Mild cognitive impairment II fMRI NCT01044758
34. Levodopa Alzheimer’s disease IV fMRI NCT00306124
Levadopa Tourette’s syndrome NI fMRI NCT00634556
35. Lidocaine Healthy NI fMRI NCT00725504
36. Lithium (Quetiapine) Bipolar mania IV fMRI NCT00609193
Lithium Bipolar disorder IV fMRI NCT00596622
Lithium Bipolar disorder IV Morphom NCT01543724
Lithium Multiple systems atrophy II fMRI (RSN) NCT00097672
Lithium Spinocerebellar ataxia 2 II fMRI(RSN)/Morph NCT00998634
37. Lidoderm Back pain IV fMRI NCT01515540
38. Lisdexamfetamine Bipolar depression IV fMRI NCT01051440
39. LY686017 (NK1 antagonist) Alcohol craving II fMRI NCT00310427
40. Methylphenidate (children) ADHD IV fMRI NCT00778310
Methylphenidate TBI memory NI fMRI NXT00453921
41. MDMA (3,4-Methylene dioxymethamphetamine Addiction I fMRI NCT01148342
42. Milnacipran Fibromyalgia III fMRI NCT00793520
43. MK3134 (Donezapil) Cognition I fMRI NCT00887601
44. Morphine Healthy IV fMRI NCT01245244
45. N-Acetyl cysteine Schizophrenia IV fMRI NCT01339858
46. Nefazodone Social anxiety disorder IV fMRI NCT00231348
47. Naproxen Osteoarthritis 0 fMRI NCT00830050
48. Oxytocin Autism I fMRI NCT00263796
49. Oxytocin Social cognition I fMRI NCT01606462
50. Paracetamol Healthy I fMRI NCT01562704
Paracetamol Pain/healthy I fMRI NCT01562704
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will be the comparison in future studies of healthy vs patient
data for the effects of drugs to determine the value of healthy
subjects as has been evaluated previously for non-CNS-
acting drugs using a pharmacokinetic model.49 Imaging can
provide this comparison in relatively few numbers of patients
(Figure 2). Thus, imaging can provide a bridging process
between the healthy and patient populations to determine
appropriate dosing in the patient population (who differ from
healthy controls) before designing phase II efficacy trials.50
This is particularly critical in CNS disorders such as major
depressive disorder, where often half of the subjects are in
the obese range of body mass index, in contrast to the typical
leaner populations serving as healthy controls.
Phase II
In phase II trials, evaluation of the drug in patient populations
is undertaken: ‘The experimental study drug or treatment is
given to a larger group of subjects (100–300) to see if it is
effective and to further evaluate its safety’ (http://clinicaltrials.
gov). Major issues here relate to measures of understanding
efficacy rates, particularly, in the context that these trials are
usually not that long in nature (see Figure 3). Without an
objective marker, subjective ratings continue to be used, with
consequences that include features such as large variance,
poor inter-rater variability and rater biases. The diagnosis of
most CNS disorders is based on the subjective interpretation
of signs and symptoms on the part of the clinician. Even when
Table 1 (Continued )
Drug (comparators) Indication Phase Imaging modality ClinicalTrials.gov identifier
Paracetamol Osteoarthtriis IV fMRI NCT01105936
51. Paroxetine PTSD IV fMRI NCT00700999
Paroxetine Depression IV fRMI NCT00429169
52. Pioglitazone Cognition I fMRI NCT01456117
53. Pituitary adenylate cyclase-activating polypeptide-38 (VIP) Migraine NI fMRI NCT01471990
54. Pramipexole (Amisulpride) Obsessive compulsive disorder I fMRI NCT00471588
55. Pregabalin Neuropathic pain NI MRS NCT01180608
Pregabalin Fibromyalgia I MRS NCT00760474
Pregabalin Anxiety IV fMRI NCT00706836
Pregabalin (Tramadol) Traumatic neuropathy IV fMRI NCT00610155
56. Quetiapine Depression IV fMRI NCT01200901
57. Razadyne (Aricept) Alzheimer’s IV fMRI NCT00369603
58. Risperidaone Autism II fMRI NCT01171937
Risperidone Autism spectrum disorders II fMRI NCT01171937
59. Rivastigmine Alzheimer’s NI fMRI NCT00627848
60. RO4917523 (escitalopram) (methylphenidate) Depression IIa fMRI NCT01045083
61. RO5285119 Healthy I phMRI NCT01418963
62. RPh201 Vegetative state I/II fMRI NCT01438684
63. Sapropterin Phenylketonuria NI fMRI/DTI NCT00730080
64. Scopolamine (Donazepil) Healthy/cholinergic function NI ASL NCT01379001
65. Sertraline PTSD IV fMRI NCT00391430
66. Silbutramine Obesity I fMRI NCT00914212
67. SYN115 Parkinson’s disease II fMRI NCT00605553
68. Valproate Bipolar disorder IV Morphom/MRS NCT00431522
69. Varenicline Alcohol addiction I/II fMRI NCT00695500
70. Vyvanse mTBI III fMRI NCT01000064
Abbreviations: ADHD, attention deficit hyperactivity disorder; ASL, arterial spin labeling; CGRP, Calcitonin-Gene-Related Peptide; DTI, diffusion tensor imaging;
fMRI, functional magnetic resonance imaging; MRS, magnetic resonance spectroscopy; mTBI, mild traumatic brain injury; PET, positron emission tomography;
PTSD, post traumatic stress disorder; RSN, resting state network; TBI, traumatic brain injury.
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Figure 2 Imaging healthy subjects vs patient populations in phase I. Functional magnetic resonance imaging evaluation of drug measures using healthy subjects or
patients in early phase trials (for example, (‘1a’) can provide information on central nervous system (CNS) penetration and dosing). However, the equivalence in the clinical
population may not be the same because of numerous factors (disease state, prior drug effects, altered effects on specific circuits and so on). As noted below, the use of
healthy subjects and later comparison in patients will further define the utility of early imaging for newly approved Investigational New Drugs. The later parallel and replicated
study in patients will confirm or provide data to suggest finessing dosing for later trails.
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objective tests are used, such as electroencephalography in
epilepsy and polysomnography in sleep disorders, there is
often a risk of over inclusion of atypical forms of illness, which
are more likely to have spontaneous fluctuations of symptoms
and may inflate rates of placebo response. Site clinicians’
biases to enroll subjects into trials, coupled with a system of
incentives for Clinical Research Organizations to reward
rapidity and not quality of enrollment, make clearly necessary
the independent verification of diagnosis through centralized
systems such as remote raters and/or remote reviews of
diagnostic tests. Patients enrolled in CNS clinical trials often
present with a heterogeneous group of symptoms represent-
ing several syndromes or subtypes, subsumed under the
same diagnosis in the classification system. As a result,
enrolled patients may not have the valid illness characteristics
of interest to the particular study. The recently proposed
SAFER interview method51 represents an effort to address
the problem of diagnostic misclassification in clinical trials of
psychiatric disorders. This method was developed to deline-
ate a more symptom specific and ecologically valid approach
to the identification of the valid patient for clinical trials, as
clinical drug development needs to focus on the primary
nosological entity likely to be affected by a new drug entity’s
mode of action. Neuroimaging may allow the remote valida-
tion of the appropriateness of the inclusion of study subjects
and may confirm the diagnosis. Opportunities to evaluate
circuit-based measures of efficacy, potential new indications,
make comparisons across similar or competitive drugs, and
defining measures of response (variance) can all contribute to
the traditional drug development model. In phase II studies,
patients may either be included in the overall study or smaller
‘satellite’ groups undergo imaging to determine a number of
features of the drug including functional measures, evaluating
sample size (that may change if specific imaging outcomes or
measures are added), comparison with other drugs to get an
understanding of potential competitive advantages and the
like (discussed below). Phase II trials offer an ideal opportu-
nity to integrate neuroimaging and new trial designs such
as the Sequential Parallel Comparison Design,9 thereby
providing an ability to evaluate novel therapies with greater
confidence of the validity of conclusions, before their going
into phase III trials. Examples of the use of NMR imaging in
phase II include the GlaxoSmithKline evaluation of two doses
20 and 200mg of a Corticotrophin Releasing Factor 1
Receptor Antagonist on brain responses in irritable bowel
syndrome (see Table 1). The aim of the study was to assess if
the drug-reduced/reversed stress-induced hypersensitivity in
these patients. The primary outcome defined as ‘Signal
reductions in the amygdala during viewing of emotional faces
and during abdominal pain threat as measured by the fMRI’
and a secondary outcome as ‘Questionnaires to assess
irritable bowel syndrome symptoms and anxiety’. Again the
numbers of subjects in the study were relatively few (n¼ 40;
assumed to represent both patients and controls). The effects
of the drug on brain systems in irritable bowel syndrome vs
healthy controls have been reported in a recent manuscript:52
increased activity in the hypothalamus and locus cerouleus
with placebo and decreases in the hypothalamus after the
drug that was moderated by anxiety.
Circuitry-based measures of drug efficacy. Ideally,
producing a highly effective drug with few or no side effects
would be an excellent outcome. Many drugs with good
efficacy have side effects that are only detected in later
clinical trials. Some CNS diseases are more difficult to get a
handle on where there may be diffuse processes (for
example, Alzheimer’s disease) compared with rapid symp-
tom effects (for example, movement in Parkinson’s disease,
pain and so on).
Imaging opportunity. In relatively small sample (n¼ 12–20)
patients, evaluation of both disease state and drug effects
can be performed. Outcomes such as reversal of abnormal
circuitry or lack thereof and other specific measures can be
evaluated. In addition, comparisons with other drugs or
current standards normally require large number of patients.
Although subjective measures are helpful, these are
notoriously highly variable and subjected to significant biases
Normalization
of Activation
Drug
Comparisons
Side Effects
Use of ‘best in class’ as a
comparator in small cohorts
provides insights into benefits
of new drug
Evidence for Targeted Effects
Targeted Effects
Early signs of potential side effects:
-   Emesis
-   Drowsiness
-   Addiction
-   Altered Cognition
Figure 3 Magnetic resonance imaging (MRI) measures in phase II. Top: Normalization of circuits has been observed in a few functional MRI studies, consistent with
behavioral effects.130 Middle: Comparative drug effects allows for a number of observations including (1) comparison with best in class; (2) comparison with known mechanism
of action type drugs. Bottom: Side-effect profiles may be subclinical or not significant in smaller cohorts but present as potential issues that can be defined in early studies.
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and issues of inter-rater reliability. In addition, filtering out a
circuit-based process may contribute to the evaluation of
longer-term benefits of the drug. Measures of drug efficacy
may be done through either resting state network or evoked
stimuli. The advantage of the former is that the patients
simply lie in the magnet and do not have to follow any
instructions. Therefore, for some CNS diseases where
cognitive abilities are altered, this may be a useful approach.
As noted in Box 1, resting state networks can differentiate
drug effects. Imaging can assess longitudinal changes
associated with drug use.
Sample size. Powering clinical studies usually involves
large groups of patients because of variability. One of the
big issues with clinical trials relates to the nature of the study
design and the variability of data acquired, especially in
subjective ratings.53–55 Clearly diminishing variance allows
for a number of benefits including fewer patients required for
adequate power of the study and fewer patients are exposed
in a drug trial. Both elements have important cost-related
benefits. Much of the variance has to do with factors such as
inappropriate phenotyping of the population being studied,
measurement error, inappropriate end points, problems with
responders and non-responders, placebo response, quality
of data collected even with good clinical practice standards56
including timeline for evaluation of responses.57
Imaging opportunity. Imaging data can help decrease the
variance within a study population by determining brain
changes of drug vs placebo with or without correlations with
subjective measures. Such data have come from some
studies in healthy subjects in a paradigm evaluating pain
using imaging, where activations showed less variance than
pain reports.22 By implementing novel designs and end
points for phase II trials would improve efficiency in defining
those New Chemical Entities with potential and quickly
eliminating those that have limited efficacy (see Adjei
et al.58). Adding imaging (markers/biomarkers) into this part
of the clinical development and specifically defining new end
points. The evolution of this type of approach may also help
in identifying responders and non-responders at an early
stage for methodological considerations in larger phase III
trials. New analysis techniques will also allow segregating
patients according to subgroups based on their brain nasal
states and responses to treatment.59
Early comparators: differentiation of new entity with
‘Best in Class’ or mechanism of action. The placebo-
controlled trial has been the standard method to demonstrate
efficacy and safety, that is, most CNS clinical trials evaluate
New Chemical Entity with a placebo (‘A placebo is an inactive
pill, liquid, or powder that has no treatment value. In clinical
trials, experimental treatments are often compared with
placebos to assess the treatment’s effectiveness’ http://
clinicaltrials.gov). Few CNS trials include an active comparator
(see Leon60). So-called ‘active-control non-inferiority trials’ take
this into consideration.61,62 phMRI data sets are accruing in
a non-defined or non-organized manner (see Table 1), but
nevertheless are providing the initial contributions to what
could be the development of drug-specific databases that
could be used as comparators for new drugs. Many CNS drugs
have actions on the CNS that are not well understood.
Imaging opportunity. Data banks on CNS activation of drugs
that are now in the non-competitive space can provide a
basis for evaluation of new drugs. Thus, the cumulative
benefits, particularly if there is the development of a
databank, could really help to understand in-vivo drug action
in the CNS.
Drugs and clinical relevance: the need for phenotyping
and biomarkers. Most drugs are focused on specific
targets. Take the antidepressants as an example. The initial
appeal of an aminergic target certainly seemed to be valid.
Certain aspects clearly questioned the process including the
time lag for efficacy. More recently, neural circuit adaptation
has been postulated as a process that underlies the potential
efficacy of antidepressant drugs. We now have a method to
evaluate this. However, and perhaps, equally important is to
understand that when we evaluate a drug in a particular
population, these patients are of a particular ‘phenotype’.
This seemingly obvious issue is difficult without the enabling
processes afforded by biomarkers.63,64 The development of
biomarkers for CNS disease would revolutionize the
approaches being taken in the drug development domain.
Certainly, attempts in different domains are currently at the
forefront of many research enterprises across the CNS
domain. It is unlikely that many CNS disorders will have a
single gene entity that can define the disorder like hemiplegic
migraine or erythromelalgia or certain Parkinson’s disease
subtypes. Thus, other markers are essential to define the
clinical phenotype in an objective manner. Accurate pheno-
typing is critical to any drug trial (see Founti et al.65). Imaging
is one opportunity in the development of biomarkers for drug
development.66–68
Imaging opportunity. Currently, imaging offers a basis for a
‘marker’ of drug effect. It has not developed yet to a level of an
accepted, regulatory-approved biomarker. Recent advances
suggest that imaging may contribute to improving success
rates in drug development, but for this to happen, biomarkers
need to be defined, validated, reproducible and adopted by
regulatory agencies. Figure 4 conceptualizes the use of
imaging biomarkers in drug evaluation. The approach may
also evolve to have disease fingerprinting69 or disease evolu-
tion utilizing anatomical measures.70 Indeed, the Alzheimer’s
Disease Neuroimaging Initiative has provided a model for
applications of imaging in disease and drug evaluation.71
Phase III
In phase III trials, ‘the experimental study drug or treatment is
given to large groups of people (1000–3000) to confirm its
effectiveness, monitor side effects, compare it to commonly
used treatments and collect information that will allow the
experimental drug or treatment to be used safely’
(http://clinicaltrials.gov). Here tremendous opportunities exist
to add imaging information to clinical trial design improve
study information. Issues pertaining to predicting natural
course of the disease (for example, improvement independent
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of treatment), predicting responders vs non-responders
based on an objective metric can, as in phase II trials, be
incorporated into phase III trials. Examples of the use of NMR
imaging in phase II include those listed in Table 1; as noted
from the table, there are relatively few phase III trials (see
section ‘Limitations of NMR imaging in drug development:
difficulties to overcome as a useful tool in clinical trials’ below).
Temporal course of CNS diseases. Symptoms of most
CNS diseases fluctuate over time; they are for the most part
progressive (for example, Alzheimer’s disease) or may be
intermittent in severity (for example, depression) or may have
a natural course that trends toward improvement (for
example, chronic pain or migraine; see Parkinson’s Progres-
sion Marker Initiative—that involves measures of imaging
and other potential makers72). Thus, understanding if the
drug has an effect during the trial or the change is a response
to the fluctuation of the disease can critically affect response
measures that may have little to do with the drug effect (see
Johannsen et al.73). The issue may be implicated in the
failure of clinical trials74 because of changes in clinical status
(see Kemp et al.75 and Geisser et al. 76). Such changes may
make the disease more resistant or less resistant, or in some
cases may revert to a ‘normal’ level, as is the case with
chronic pain or depression.
Imaging opportunity. Imaging can provide a specific effect of
a drug or intervention (Figure 5). For example, the evolving or
normalization of a network that may take place as a result of
the drug treatment or for other reasons including sponta-
neous disease remission (for example, in depression).
Ideally, imaging can provide two useful measures: (1)
specificity of early markers of drug action and (2) disease
state or drug effects over time.
Imaging as an effective measure of drug response.
Although placebo-controlled trials have been considered a
standard for evaluating a drug, the improved understanding
that the placebo effect may be a specific response of a
subject based on psychological processes that drive neural
systems.77–79 Differentiating drug–placebo differences are
more difficult in the CNS domain80–82 than placebo. As shown
in Figure 6, one may classify treated subjects in a CNS
clinical trial based on each subject’s propensity to respond to
a given type of treatment. The D-P-population comprises
subjects who are not responsive to both active and inactive
treatments. In CNS trials in non-resistant neuropsychiatric
disorders, the DP group typically represents 50% of the
populations, based on the non-response rates frequently
observed with active treatments. Such proportion, naturally,
tends to be larger in more resistant populations. The DþPþ
population comprises subjects who are responsive to either
active or inactive treatments. In a very large meta-analysis of
182 antidepressant clinical trials pooled (n¼ 36 385) from our
group,83 the average placebo response rate in trials with two
active treatments and placebo was about 40%, which is a
proxy for the rate of DþPþ group. When the placebo
response (and therefore the DþPþ group) is 40% in a given
clinical trial, and the DP group is 50%, this means that
only 10% of the treated subjects belong to the DþP group,
which includes patients who respond to active treatment but
not to placebo. Therefore, the higher the placebo rate, the
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Figure 4 Biomarkers and central nervous system (CNS) drug development (modified from Borsook et al.63). Imaging biomarkers for specific CNS disease are the focus of
a number of research initiatives (Parkinson’s disease;131 Alzheimer’s disease;132 depression;133 pain63,64). However, with the exception morphometric imaging in Alzheimer’s
disease, few have yet to be adopted by regulatory agencies. Nevertheless, the Food and Drug Administration’s critical pathway initiative has encouraged the development and
use of imaging in drug trials through their Alzheimer’s Disease Neuroimaging Initiative program (http://www.adni-info.org). Having validated biomarkers of the disease state
(imaging or other) will contribute enormously in clinical trials.
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smaller the size of the DþP group, the only informative
group of patients. Thus, if the average placebo response rate
in antidepressant trials is 40% or greater, this means that
more than 50% of these adequately powered trials cannot
possibly detect a signal, even when the compound is active,
as 10% or less of the sample is informative. How can one
improve outcome of category: (1) through differentiation of
category, (2) by defining responders to the drug being
evaluated vs responders to the placebo. Thus, the issue
may be defined in terms of differentiation of responses and
responders. These are seemingly straight forward; however,
false positive (a good result reported when there actually is
not one) and false negative responders (a poor result when
there is actually a positive one) complicate the issue.
Furthermore, evaluating responders vs non-responders also
relates to the heterogeneity of the disease. A major issue
related to response is the level of response—is it a complete
response (the absence of the symptoms of the disease).
Furthermore, a response may be relatively short lived for
various reasons that may include pharmacodynamic, tachy-
phylaxis and alterations in response because of the course of
the disease over time.
Imaging opportunity. Although the placebo (an inactive
pill, liquid or powder that has no treatment value
(http://clinicaltrials.gov)) would ideally be expected to show
no effect because it is an inert substance, the placebo effect
can confound results. Differentiation of the placebo effect
(‘A physical or emotional change, occurring after a substance
is taken or administered, that is not the result of any special
property of the substance. The change may be beneficial,
reflecting the expectations of the participant and, often, the
expectations of the person giving the substance’
(http://clinicaltrials.gov)) from the drug effect can be proble-
matic. The effect of placebo response rates and how best to
measure this in clinical trials has made clinical trials of the
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(Progression or Disease State)
D
ru
g 
Ef
fe
ct
Figure 5 Imaging markers of disease course. Many central nervous system diseases have a progressive and/or undulating course that includes partial or complete
remission. A clinical study based on subjective criteria cannot adequately (objectively) evaluate drug effect on disease load (how severe or a relative stage of progression of the
disease). These are important factors as for the same dose of a drug (as shown in the lower panels) the effect on brain systems may show diminished efficacy based on
disease load. Importantly, such efficacy may be enhanced over time as the drug may have effects over time.
Drug Placebo
Outcome 1 Outcome 2 Outcome 3
Population with
Nonspecific
response
Population
non-responsive to
treatments
Population able to
differentiate Drug
from Placebo
Figure 6 Classification of populations based on propensity to respond to types of treatment (drug (D) or placebo (P)). In controlled trials, differentiation of D from P effects
can be difficult. Part of the reason for this is that drugs do not provide high degree of efficacy that make this differentiation obvious. As noted above, reasons include three basic
outcomes: outcome 1: clear differentiation of D vs P; outcome 2: unclear differentiation of D vs P; and outcome 3: unclear differentiation of lack of efficacy. Taken together, the
contribution of outcome 2 in particular, because of lack of effective methods to differentiate D from P, can contribute to a false negative result of the trial.
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CNS a more complex issue.84,85 As noted in Figure 7, some
patients show clinical improvement in response to the
placebo arm of a trial where an inactive compound is used.
The variability in placebo response rates in CNS clinical trials
may vary.3 The large variation makes the trial design
challenging because of adequate statistical power and
sample size requirements. Furthermore, if patients are not
adequately screened or phenotyped, further variation in
response to placebo may be observed (for example, between
anxious vs non-anxious patients).
Symptom effects vs disease modification. There is no
question that the quality of life can be significantly elevated
with the control of symptoms. Measures of disease modifica-
tion that stabilize, limit or reverse or prevent a CNS condition
are clearly sought after75,86 and are clearly challenges for
neuroscience and pharmaceutical industries involved in
CNS-related therapies.87 To date, however, there are no
drugs that completely alleviate disease symptoms (for
example, pain, depression and so on). Ideally, treatments
that effectively reverse the condition would be a transforma-
tional in nature. The problem is that, for the most part, unless
some phenomenal genetic or stem cell-type approach
emerges, for most pharmacotherapeutics, the process will
in all likelihood be slow.
Imaging opportunity. Whatever the disease-modifying treat-
ment approaches are used, stem cell, biologicals and so on,
defined measures will be required to evaluate disease
modification over time. For some diseases (that is,
Alzheimer’s) prior work has provided some useful insights
into the use of morphometric measures for drug effects on
disease outcome (see Cummings88 and Weiner et al.89).
Given that most CNS disorders are chronic in nature, brain
measures of function and structure can be enormously
helpful in measuring progressive changes. In addition, the
benefits of multimodal imaging can provide congruent
measures on the disease condition or a drug effect. For
example, magnetic resonance spectroscopy (see Box 1) can
provide a correlate of alterations in gray matter volume
changes; gray matter volume changes may correlate with
alterations in white matter connectivity that then has
implications on functional processing.83,90,91
Dosing and drug effectiveness. Once patients are pre-
scribed drugs, they frequently stay on these medications
without assessment of how they have altered the brain.
Recent data, for example, have questioned the use of some
drugs over the long term because of negative effects on brain
systems. As such the opportunity to evaluate new
approaches to drug therapy, with continued but lower doses,
may contribute to equal or even higher efficacy rates in
patients for a number of reasons including limiting side
effects and thus compliance.
Imaging opportunity. Imaging would provide measures of
efficacy in chronic long-term dosing. The issue of long-term
medications on the brain (for example, opioids) or long-term
consequences of medication (for example, methylphenidate
or anesthetics in children) clearly need to be established.
Many medications are taken as prescribed for years without
evaluation of potential good and bad effects. This is critical as
the drug might induce positive changes (that is, tendency or
return to ‘normal’ brain function) or negative ones (for
example, migraine chronification from medications including
chronic opioids, chronic triptans92,93).
Implementing integrative imaging in clinical trials
As noted by Kuhlman94 ‘The more thorough and profound
studies have been carried out during this exploratory stage of
development, the earlier a decision can be made on the
continuation or discontinuation of further development. Taking
responsibility as the link between research and development
gives clinical pharmacology a major opportunity to assume a
pivotal role in research and development of new drugs’ Drug
development has been a sequential process that has included
preclinical evaluation (target selection, toxicity profiling for
safety and side effects), FIH trials that include drug escalation
for maximum tolerated dose (phase I, usually in healthy
volunteers), drug efficacy in patients (phase II), efficacy and
safety (phase III, with a specific indication usually for
regulatory approval) and post-marketing evaluation to deter-
mine no unexpected side effects (phase IV). Ideally, the more
information that can be collected in early trials predicting
outcomes (both good or bad), the more efficient and less
costly the process (as information may arise halting the
program early or forcing an evaluation that may change the
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Figure 7 Differentiation of drug effects vs placebo effects with imaging. An
imaging readout can define a drug effect or placebo effect. More difficult is a placebo
response where drug and the induced placebo response may be similar because
similar pathways are involved (for example, in opioids analgesics). However,
differences in responders vs non-responders based on integrating subjective and
objective (imaging readouts) can help segregate true drug effects from placebo
responses. Patients could be segregated into responders and non-responders
according to psychometric criteria. Imaging their response to a drug challenge will
further allow the determination of specific changes in brain activation and networks
as compared with a placebo arm or to non-responders. It will be expected that non-
responders will present a reduced drug effect as well as potential differences in
brain networks responses. The inherent difference of responders vs non-responders
will also be reflected as difference in brain activity patterns and networks even to a
placebo challenge. One of the issues raised in this differentiation is whether drug
non-responders are more resistant and thus require increased doses.
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trial or even the indication) (Figure 8). Most trial phases are
usually planned and implemented separately, potentially
diminishing the benefits of a sequential integrated approach.
Transferring useful information including imaging information
across development would necessitate an integrated
approach to the process. Figure 9 summarizes key points
that imaging can bring to the evaluation of a CNS drug
candidate in drug development. In other domains of clinical
trials, some have supported a role for translational research
across the various phases of clinical trials.95
Biological considerations
Comparative studies across drugs and conditions. The FDA
has encouraged the use of biomarker approaches to drug
development. Hopefully over time, pharmaceutical and
biotechnology companies will provide more exciting and
useful information on how imaging can help make smart
choices in drug development. Through such processes as
well as evaluation of drugs in academic centers, an
accumulation of a body of knowledge on drug ‘fingerprints’
on brain systems will allow for a Brain-Drug-Catalogue. The
value will be to provide a comparative evaluation of similar
drugs (by class or by mechanism of action) in which to
compare new drugs. Perhaps this may even become a
process that will achieve a consensus to be performed in all
phase II studies. Such comparisons could also apply to bio-
similar products.
Integrated multimodal imaging approaches. As imaging
technologies develop, rapid magnetic resonance sequences
can capture a number of brain functional, structural and
chemical measures. Integrating such measure can provide
further information including response to drugs, predict
responders vs non-responders, or early changes in brain
systems that may be markers of drug efficacy. More sensitive
imaging technologies have already provided novel insights
into stroke severity and prediction of outcome, the nature of
underlying brain changes in mild traumatic brain injury and so
on. Alterations in structure usually accompany changes in
function (see Upadhyay et al.32).
Early evidence of subclinical side effects. Many CNS drugs
fail because of side effects. Some brain-defined side-
effects (for example, nausea and vomiting, drowsiness) or
unwarranted effects (for example, addition, cognitive
changes) can be observed in imaging in small groups of
subjects as potential changes would focus attention in early
trials and allow for changes to be made in the larger trial
design (for example, dosing) or for the drug to stop in its
development based on these appraisals. The flip side of this
is that unexpected side effects can provide new insights into
brain systems and human surrogate models. Perhaps a
good example of this is the antimalarial agent mefloquine-
producing drug-induced psychosis in otherwise healthy
subjects.96,97
Clinical trials considerations. A number of issues arise
when considering imaging in clinical trials. The first is
integration of imaging into trials without confounding
regulatory processes and including risks to the trial. If done
in a manner that can show enhanced outcomes, this could
lead to fewer patients to be exposed to new drugs early in
clinical trials (for example, phase II). The second is applying
good imaging practice in trials98,99 to ensure standards
across the industry. As noted in Table 1, there are more
clinical trials using imaging, but this is still relatively new and
on an ‘ad hoc’ basis without agreed upon standards and
known measures such as sensitivity and specificity (see
above). The data listed in the Table 1 are derived from all
registered trials from clinicaltrials.gov (http://www.clinical-
trials.gov; see details in section ‘Where we are now?’ below).
The third issue that imaging may evolve into is the validation
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Figure 8 Use of imaging in drug development (adapted from Borsook et al.64). Imaging can define brain regions involved in symptomatic effects before these become
subjectively apparent because of specific circuits activated and their progress to correlative changes with symptoms at a later stage. CNS, central nervous system.
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of surrogate end points. Such information provides a
correlate of a clinical end point and is defined as ‘a biomarker
intended to substitute for a clinical end point’ (see Lesko
et al.100 and Lathia et al.101).
Financial considerations
Risk-benefit assessment aided by objective metrics.
Decreasing the risk of drug development including the ability
to get objective data from relatively small cohorts of
individuals, the cost benefits of discontinuing work on drug
are critical elements in go–nogo decisions. Obviously,
decisions to fund trials are critical to financial success of
the drug. However, the risk for investigational drugs is high,
especially in the CNS domain where the overall success
rates has been around 15%.102 The average cost of a drug
from inception/discovery to approval following phase III trials
is close to a billion dollars. The costs of drug development
from discovery to phase II trials is around $100 million. At
least three pharmaceutical companies initiated clinical drug
development efforts of NK-1 receptor antagonists for a pain
indication. The total number of patients evaluated for NK-1
Receptor Antagonist for pain in known investigator-initiated
or company-initiated phase II clinical trials is based on
available data in the public domain is around 500 individuals
(see Borsook et al.38). If one assumes an investigator
(academic, Clinical Research Organization) costs of appro-
ximately $25 000–$35000 per patient, it is around
$12500000–17500000, notwithstanding, the potential risk
for side effects that overall is reported to be relatively minor
(for example, diarrhea). These do not take into account a
pharmaceutical company’s costs; estimates are $17million
per year on drugs in phase I, $34million on drugs in phase II
and $27million per year on drugs in phase III of the human
clinical trials.103 Thus, in the case of the NK-1 receptor
antagonists, a conservative estimate of the phase I–II trials
across four companies is estimated to cost over $100 million.
Given the extremely low-side-effect profile of the drug and
early preclinical suggestions of alternate indications, the drug
has successfully made it into the antiemetic arena, and looks
promising in other areas of psychiatric disease. The
additional costs for fMRI of a small group of subjects in
early phase development (drug has received Investigational
New Drug and therefore can be administered to subjects) is
around $1 million. However, the potential cost-benefits based
on the data obtained at this early stage may be enormous
(see Borsook et al.38).
Limitations of NMR imaging in drug development:
difficulties to overcome as a useful tool in clinical trials
Although the potential of imaging across the three phases of
clinical trials may be great, enthusiasm should be tempered by
current limitations or issues that need to be improved or
overcome. Some of these are noted below and in Box 2.
Technical issues. With all imaging methodologies that
measure indirectly brain activity through physiological
changes, the underlying issue relates to how much of the
change is neural vs physiological. This is especially
important in clinical trials in which drug effects are assessed
as the drug itself might induce global physiological changes.
Although blood oxygenation level dependence is the main
approach to perform fMRI experiments, it could be highly
affected by drugs altering brain perfusion or reactivity in any
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Figure 9 Integrating imaging for central nervous system (CNS)-related clinical trials (modified from Borsook et al.64). (1) Phase Ia and imaging—Defining CNS targeting in
small groups (o12 subjects); from these studies information on CNS penetration (as evidenced by activation in putative target brain regions); CNS dosing (as determined by
correlative measures of plasma PK and CNS effects); and CNS ‘target interactions’ as determined by brain regions activated by drug (particularly useful if drug is not amenable
to positron emission tomography methods) that may be positive (therapeutic) or negative (side effects). (2) Phase II and imaging—Early insights into efficacy and side effects.
Specifically, knowledge of how a drug activates circuits postulated to affect disease; early objective measures of responder vs non-responder; combined with subjective
measures decreases the variance and thus fewer subjects needed to adequately power the study; and imaging defined markers of potential side effects (for example,
drowsiness, addiction potential, nausea and vomiting, cognitive changes and so on); (3) Phase III and Imaging—Responders vs non-responders can further be differentiated.
(4) Phase IV and Imaging—Disease modification. PD, pharmacodynamics; PK, pharmacokinetics; SE, side effects.
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manner. Several approaches exist to mitigate or quantify
physiological effects on blood oxygenation level-dependent
signals and include: the recording of physiological para-
meters (heart rate, blood pressure, end tidal CO2 and so on)
to be considered in the analysis, the addition of control
scans/experiments of systems that are not affected by the
drug and should remain constant (for example, visual system
activation) or measure actual physiological changes in brain
perfusion such as blood flow measurements with arterial spin
labeling. Another technical issues potentially affecting
neuroimaging measurements include patient compliance:
excessive motion, not following instructions could affect or
render useless the acquired data set and without proper
monitoring during the scans such data sets can contaminate
the overall assessment. However, new imaging analytic
approaches including machine vector learning can now be
employed to objectively differential subjects, disease subtype
and drug effects.104,105 Such developments when deployed
into the drug trial armamentarium should significantly help
further the use of NMR imaging in clinical drug development
at the individual and population level.105,106
Correlation with disease pathology. We acknowledge
that we do not presently have a good understanding of the
pathophysiology of the majority of psychiatric disorders.
Recently, there has been a change in the field to move from
discrete disorders to dimensions and continuous degrees
of dysfunction (for example, Research Domain Criteria).
Research domain criteria is an approach that aims to define
basic dimensions of functioning to be studied across multiple
domains of analysis (that is, genes to neural circuits to
behaviors). This certainly will impact on the role of imaging in
drug development. The correlation of current science and
disease with respect to imaging has seen breakthroughs
such as markers of disease progression (for example,
Alzheimer’s disease)107 or regression (for example, chronic
pain)108 and such brain metrics may correlate with changes
in gray matter volume that may correlate with dendritic
arborization by disease or stress109,110 or drugs;111 changes
in systems involved in known processes related to the
disease (for example, stress and hippocampal changes112).
Standardization and harmonization. Likely for phase III
studies, a multisite approach will be the approach. The use of
different scanner manufactures, imaging protocols, could
result in an exceeding variance that renders the data
unusable. Harmonization of scanner parameters, following
validation of imaging sequences across manufacturers, will
significantly reduce this problem. The need to define
standard methodologies for good imaging practice is
essential in order to understand and compare results.
A procedural framework for good imaging practice has been
suggested.113,114 If the applications of NMR measures in
clinical drug development are to be implemented, accepted
guidelines would need to be adopted. Adoption of such
standards will become necessary for imaging to be incorpo-
rated into regulatory processes and acceptance by the FDA
(http://www.fda.gov) and EMA (http://www.ema.europa.eu).
With respect to the latter, issues that will need to be accepted
include definition of imaging end points. The issue is not that
imaging would usurp clinical end points, but may enhance
the process by which clinical end points are reached.
What value would the imaging add to clinical mea-
sures? It is not argued that imaging would replace current
clinical outcomes, but improve the clinical trial approach by
decreasing the risk of the trial to both patients and the
drug developers. Right now having an objective diagnosis
for many CNS disease states has eluded us, particularly, for
psychiatric disease. In the complexity of comorbidity for
Box 2 Uses and limitations of NMR imaging
Modality
Task/evoked Specific responses to engaging network
associated with inputs
Specific responses, but variability may miss effect
Rest Basal brain state potentially
Altered by disease or drug effect
Not associated to a particular effect; potentially
Identify side-effect profiles
Reproducibility Could be high but varies with condition, across
sites
Depends strongly in harmonization of protocols parameters116–118
Sensitivity It varies according to the structure of interest
(size, location), the effect being
measured.119,120
Fairly small structures with weak effects will likely not be detected
Specificity Higher magnetic field scanners
Allow for higher spatial and temporal
Resolution
Extremely high magnetic field allows sub-millimeter resolution121–123
fMRI metrics Measures neural effects indirectly Confounded by systemic hemodynamic effects, but new analytic
approaches can account for this.
NMR systems available at most centers
phMRI activation A measure of drug–receptor interactions and down-stream effects;
phMRI measures regional and network interactions and may be
considered a top-down approach vs bottom-up approach
Standards Need for standards acceptable to industry Implementation of standards for drug and disease evaluation
(see113,114)
Specificity of
neural targets
activated
Definition of metrics for signal for a specific brain
region or network
Many diseases have co-morbidities and these need to be defined (for
example, frequency, low or high states and so on)
Clinical phenotype Definition of patient phenotype Standards for recruitment and classification in trials needs to be
improved; this applies to all clinical studies; lack of understanding of
pathology of many CNS diseases
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many diseases including neurological disease is a critical
issue. For example, in most neurological diseases, comorbid
depression is present.115 In addition, disease state varies
over time, and therefore evaluation of a drug targeted against
a specific disease may have a different efficacy profile
depending on the ‘intransigence’ of the disease that relates
to its duration and severity. Similar issues may relate to
sensitivity of side-effect profiles. Finally, clinical measures of
disease modification are difficult to determine and imaging
may have a specific niche in this domain. Trials in
Alzheimer’s disease (refs) and chronic pain (refs) have
provided some examples of specific morphometric measures
of such changes.
Validity and acceptance. NMR imaging meets some of the
Daubert Criteria for use in a legal sense (http://www.law.
cornell.edu/wex/daubert_standard) in that it can be tested
and therefore validated and the procedure can be peer
reviewed. Issues pertaining to the rate of error for NMR
imaging in patients or for drug effects is a path forward but
that needs to be further evaluated and defined. Although
NMR imaging is generally accepted in some of the scientific
community, it has not made it to routine clinical use at this
time. More stringent measures of sensitivity and specificity
will allow for this, and for its potential use in drug
development, its acceptance as a method and potentially
as a biomarker by regulatory agencies.
Where we are now?
Table 1 is data collated by searching http://www.clinicaltrials.
gov; the search strategy was performed in two phases; the
first was for trials listed, a search strategy included ‘fMRI’,
‘phase I’ or ‘phase II or phase III’ and ‘drug trial’; the second
was a cross check for specific diseases (for example, pain,
depression) and for age groups (for example, children). The
table provides a number of interesting insights into the use of
imaging in evaluating drug effects. As noted in the table, some
70 drugs are represented, suggesting a reasonably active use
of fMRI in drug evaluation, use that has really increased
steadily since 2010.
First, a number of companies are using fMRI to evaluate
novel drugs. Examples are those being developed by Novartis
(#), Glaxo-Smith-Kline (#24–27, 29), Astra-Zeneca (#7), Eli-
Lilly,29 Merck (#43), Hoffman-LaRoche (#’s60, 61) and some
smaller biotechnology companies (Biotie Therapies Inc., #67).
This does not include other drugs being evaluated for chronic
disease at Academic institutions supported by pharmaceutical
companies or the NIH. Thus, it would seem that despite
ongoing reservations, the use of fMRI, albeit in a limited
manner is gaining acceptance across the pharmaceutical
industry. Although this adoption may be as an ‘add-on’ to
standard approaches in clinical drug development, more
experience and data will provide further insights into the utility
of the approach. A recent paper epitomizes ongoing efforts to
further understand the utility of imaging in drug development:
‘Quantifying the attenuation of the ketamine phMRI response
in humans: a validation using antipsychotic and glutamatergic
agents’124 and test–retest reliability to the same drug in
healthy subjects.125 Thus, through these developments,
specific assays for drug evaluation are contributing to greater
acceptance in the field.
Second, the use of the technology spans all phases of
clinical drug development (see Table 1; phase 1: n¼ 25
studies; phase II: n¼ 11 studies; phase III: n¼ 4 studies; and
phase IV: n¼ 34 studies). As noted from Table 1, all clinical
phases (phase I: n¼ 25 studies; phase II: n¼ 11 studies;
phase III: n¼ 4 studies and phase IV: n¼ 34 studies). Some
studies noted in clinicaltrials.gov are listed with no phase
defined and some are listed as combined (that is, I.II). The
frequency spread on the use of imaging toward early phase (I)
and later phase (IV) may relate to regulatory processes
imposed by the FDA or its European equivalent, the EMA. The
relative value of use of imaging at different phases is still
unclear. Costs of adapting this will probably offset those of
ongoing trials that would have either been halted or redirected
with insights from functional imaging, the NK-1 receptor
antagonist providing a good example.126
Third, use of the technology for drugs with different
indications (see #’s 5, 6, 11, 18, 19, 20, 22, 30, 33, 36, 40,
50 and 55) is observed in addition to the use of comparator
drugs (for example, 3, 5, 6, 7, 9, 17, 22, 24–26, 423, 54, 55, 60,
64). Notable among these are those that are in pharmaceu-
tical trials. The use of a comparator (either by function or best
in class) allows for the evaluation of new insights into a drug
being developed. For example, many CNS-acting drug have
no clear definition of how they affect brain systems and
therefore function in the short and long term. Imaging can
define such parameters that may be difficult to ascertain
clinically Thus, for example, the evaluation of antidepressants
in clinical trials may be helped with the added objective assay
in terms of producing a more effective agent.
Fourth, the technology is being used in children and adults.
Obviously, many of themajor CNS disorders such as attention
deficit hyperactivity disorder, autism spectrum disorders,
chronic pain (for example, abdominal pain) are conditions
that have few effective drugs, and methods to enhance the
clinical trial process that includes imaging, may provide useful
methods of targeting more effective drugs. This is obviously
not an ‘an alone state’ but dependent on our understanding of
neurobiology of disease. The latter has seen advances across
many CNS disorders, but clearly this area is still a major
confound.
Fifth, for some uses, a model of disease can be defined as
exemplified by #12 and the mefloquine example noted above
where a drug produces an abnormal brain state.127,128
Imaging can provide a method for assaying circuit function,
a basis for behavior. The use of healthy human surrogates in a
safe and effective manner to produce reversible alterations in
brain function may provide novel insights into disease
process, but also models to test drugs without other con-
founds such as duration of disease, co-morbidities and so on.
Sixth, what is clearly missing from the current state is how
best to integrate information from genetic, questionnaire,
phenotypic and other criteria currently used to enroll patients
into clinical trials. This is clearly an area of opportunity that
is being deployed by some groups including ours at
Massachusetts General Hospital (Clinical Trials Network
and Institute; http://www.massgeneral.org/psychiatry/research/
ctni_home.aspx).
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Conclusions
We have reached an exciting point in the potential application
of NMR technologies in clinical drug development. As the new
tool is applied, hurdles will need to be overcome if it is to be
accepted into clinical and regulatory programs. There is no
doubt that all in the industry would like to see more effective
drugs in those areas such as the CNS where a major
deficiency currently exists across most brain diseases.
Resources have been poured into similar drugs (for example,
opioids for pain, anti-depressants and so on) that may not be
more efficacious, but have elements of ease of use and fewer
side effects. Finally, future uses of ‘some complementary
techniques (such as arterial spin labeling and magnetoence-
phalography) that, if used in conjunction with blood oxygena-
tion level-dependent functional MRI, will increase the
interpretability and thus the utility of MRI for pharmacology
research’.129
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